Research programme: T-cell receptor therapeutics - T-Cypher Bio
Latest Information Update: 12 Mar 2021
At a glance
- Originator T-Cypher Bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammation
- Research Autoimmune disorders; Infections; Solid tumours